Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

6 clinical trials · Condition

Record	Firm	Date
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer (NCT03575234)	Emory University	2020-07-01
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment (NCT02917629)	National Cancer Institute (NCI)	2018-05-31
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer (NCT02567422)	National Cancer Institute (NCI)	2017-04-17
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma (NCT02775812)	National Cancer Institute (NCI)	2016-11-28
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin (NCT02381535)	National Cancer Institute (NCI)	2015-10-22
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (NCT01810913)	National Cancer Institute (NCI)	2013-03-22

Every clearance here is in the API, with alerts when new ones post.